PRP
NBIX icon

Peak Retirement Planning’s Neurocrine Biosciences NBIX Stock Holding History

Peak Retirement Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.01M Buy
29,734
+4,128
+16% +$612K 0.79% 32
2026
Q1 		$3.37M Buy
25,606
+5,989
+31% +$795K 0.67% 36
2025
Q4 		$2.78M Buy
19,617
+4,906
+33% +$711K 0.65% 37
2025
Q3 		$2.07M Buy
14,711
+2,818
+24% +$382K 0.58% 44
2025
Q2 		$1.49M Buy
11,893
+2,394
+25% +$275K 0.6% 37
2025
Q1 		$1.05M Buy
9,499
+1,869
+24% +$237K 0.58% 44
2024
Q4 		$1.03M Buy
+7,630
New +$944K 0.7% 30

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Peak Retirement Planning's NBIX Position: Q2 2026 in Review

Peak Retirement Planning increased its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, buying an estimated $612K and bringing the position to 29,734 shares worth $5.01M. The position accounts for 0.79% of the portfolio, ranked #32.

Peak Retirement Planning first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. 770 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Peak Retirement Planning held 29,734 shares of Neurocrine Biosciences worth $5.01M as of Q2 2026.
  • Peak Retirement Planning bought 4,128 Neurocrine Biosciences shares in Q2 2026, an estimated $612K.
  • Neurocrine Biosciences made up 0.79% of Peak Retirement Planning's portfolio in Q2 2026, its #32 holding.
  • Peak Retirement Planning first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Peak Retirement Planning's 13F filing for Q2 2026, filed 10 Aug 2026.